Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)	DNA Virus Infections, Disease Attributes, Genital Diseases, Head and Neck Neoplasms, Infections, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pharyngeal Diseases, Stomatognathic Diseases, Tumor Virus Infections, Urogenital Diseases, carcinoma, epithelial neoplasm, head and neck cancer, human papilloma virus infection, infectious disease, laryngeal disorder, laryngeal neoplasm, larynx cancer, mouth disorder, neoplasm, oral cavity cancer, otorhinolaryngologic disease, respiratory system disorder, respiratory tract neoplasm, sexually transmitted disease, squamous cell carcinoma, squamous cell neoplasm, viral infectious disease, viral sexually transmitted disease	Recruiting	Phase 2	2026-04-23		NCT07209189

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Coherus Oncology, Inc.	14
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	117

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Johns Hopkins Hospital East Baltimore	Baltimore	United States	1